Assessing Adherence to Adjuvant Hormone Therapy in Breast Cancer Patients in Routine Clinical Practice.
Natalia Camejo-MartínezCecilia Castillo-LeskaClara TambascoNoelia StrazzarinoNicolas RequenaSilvina PerazaAnna BoronatGuadalupe HerreraPatricia EsperónMauricio CuelloGabriel David Krygier-WaltierPublished in: World journal of oncology (2023)
Adherence to HT was assessed in real life, with 19.0% of the patients not adhering to the treatment, despite the known benefit for OS, being a well-tolerated treatment, and being provided free of charge. Older patients were associated with being more adherent. The results show the need of the Pharmacy Service and Department of Clinical Oncology Medical Oncology combining efforts to develop coordinated strategies and interventions to increase adherence, given the impact that this may have on patients' OS.
Keyphrases
- end stage renal disease
- clinical practice
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- peritoneal dialysis
- palliative care
- early stage
- physical activity
- mental health
- patient reported outcomes
- skeletal muscle
- mesenchymal stem cells
- type diabetes
- combination therapy
- tertiary care
- patient reported
- glycemic control
- cell therapy
- electron transfer